Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
| Revenue (Most Recent Fiscal Year) | $528.29M |
| Net Income (Most Recent Fiscal Year) | $-56.11M |
| PE Ratio (Current Year Earnings Estimate) | 28.16 |
| PE Ratio (Trailing 12 Months) | 115.00 |
| PEG Ratio (Long Term Growth Estimate) | 0.69 |
| Price to Sales Ratio (Trailing 12 Months) | 4.01 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 10.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5.44% |
| Net Margin (Trailing 12 Months) | -10.62% |
| Return on Equity (Trailing 12 Months) | 12.44% |
| Return on Assets (Trailing 12 Months) | 2.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.39 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.60 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.01 |
| Inventory Turnover (Trailing 12 Months) | 0.56 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.04 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 307.24M |
| Free Float | 300.48M |
| Market Capitalization | $2.12B |
| Average Volume (Last 20 Days) | 3.76M |
| Beta (Past 60 Months) | 0.79 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.20% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |